Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi^® and Canalevia^®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments

Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients

Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives

Jaguar's rare-disease pipeline is the subject of ongoing BD discussions with potential partners, targeting NDA-ready data in 12-18 months

Jaguar presenting January 22 at Sequire Investor Summit in Puerto Rico; click here to register for event

Click here to view replay of Jaguar's January 15 fireside chat during Lytham Partners Healthcare Investor Summit

$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)

Up to additional $20M in milestone and other future payments

Future Pak becomes exclusive U.S. marketer for Mytesi^® and Canalevia^®-CA1

Jaguar continues to be the manufacturer of Mytesi and Canalevia-CA1

Meaningful non-dilutive capital enables Jaguar to focus on its rare-disease pipeline, which is the subject of ongoing BD discussions with other potential partners